The need to stratify the treatment of colorectal cancer with chemotherapy, based on whether or not KRAS mutations are present, exemplifies this,” concludes Roland Wolf, the study's principal ...

The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Attention now shifts to a readout for Mirati Therapeutics' rival KRAS inhibitor adagrasib, with late-breaking data in colorectal cancer from the phase 1/2 KRYSTAL-1 due to for presentation at ESMO ...

DELHI, DELHI, INDIA, November 28, 2024 /EINPresswire / -- The Growth of the KRAS Inhibitors Market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, ...

Dr. David Kerr reports on provocative data from the FIRE-3 study indicating that cetuximab plus FOLFIRI confers a 7.5-month survival advantage in patients with wild-type KRAS colorectal cancer.

for the second-line treatment of KRAS mutant metastatic colorectal cancer (mCRC) in the peer-reviewed Journal of Clinical Oncology, the flagship publication of the American Society of Clinical ...

12,144,813 with an expected expiration date of no earlier than 2043. The claims of the patent cover the method of using onvansertib in combination with bevacizumab (bev) for the treatment of KRAS ...

Cardiff Oncology (CRDF) announced the United States Patent and Trademark Office USPTO, has issued to Cardiff Oncology U.S. patent No.

New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics –SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a ...